Benzinga | Oct 12, 2021 06:40AM EDT

HC Wainwright & Co. Downgrades Adamas Pharmaceuticals to Neutral, Lowers Price Target to $9.1

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Buy to Neutral and lowers the price target from $10 to $9.1.